Skip to Main Content
TABLE 3

Clinical characteristics and biochemical data of type 2 diabetic patients classified according to their genotypes of the −226A>G polymorphism

−226A >G genotype
P
G/GG/AA/A
n (male/female) 34 (16/18) 110 (58/52) 106 (61/44) 0.488 
Age (years) 62.4 ± 2.0 64.3 ± 1.1 62.2 ± 1.1 0.377 
Age at diagnosis (years) 45.6 ± 1.5 45.4 ± 0.9 45.6 ± 1.0 0.976 
Duration of diabetes (years) 16.7 ± 1.8 18.6 ± 1.0 16.4 ± 1.0 0.265 
Maximum BMI (kg/m227.0 ± 0.6 26.5 ± 0.3 27.0 ± 0.3 0.554 
BMI (kg/m223.4 ± 0.5 23.3 ± 0.3 23.7 ± 0.3 0.662 
A1C (%) 7.7 ± 0.2 7.5 ± 0.1 7.2 ± 0.1 0.072 
Mode of treatment (D/OHA/Ins) (n6/11/17 18/47/45 23/44/39  
Insulin (%) 50.0 40.9 37.7 0.389 
−226A >G genotype
P
G/GG/AA/A
n (male/female) 34 (16/18) 110 (58/52) 106 (61/44) 0.488 
Age (years) 62.4 ± 2.0 64.3 ± 1.1 62.2 ± 1.1 0.377 
Age at diagnosis (years) 45.6 ± 1.5 45.4 ± 0.9 45.6 ± 1.0 0.976 
Duration of diabetes (years) 16.7 ± 1.8 18.6 ± 1.0 16.4 ± 1.0 0.265 
Maximum BMI (kg/m227.0 ± 0.6 26.5 ± 0.3 27.0 ± 0.3 0.554 
BMI (kg/m223.4 ± 0.5 23.3 ± 0.3 23.7 ± 0.3 0.662 
A1C (%) 7.7 ± 0.2 7.5 ± 0.1 7.2 ± 0.1 0.072 
Mode of treatment (D/OHA/Ins) (n6/11/17 18/47/45 23/44/39  
Insulin (%) 50.0 40.9 37.7 0.389 

Data are shown as means ± SE unless otherwise indicated. P values are compared by one-way ANOVA or χ2 test for existence of insulin treatment. D, diet; Ins, insulin; OHA, oral hypoglycemic agents.

Close Modal

or Create an Account

Close Modal
Close Modal